東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Small Molecule Inhibitors Against En...

Zhu, Congrui.

FindBook

Google Book

Amazon

博客來

Small Molecule Inhibitors Against Enteric Bacterial Glycosyltransferases.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Small Molecule Inhibitors Against Enteric Bacterial Glycosyltransferases./
作者:	Zhu, Congrui.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2021,
面頁冊數:	104 p.
附註:	Source: Dissertations Abstracts International, Volume: 83-01, Section: B.
Contained By:	Dissertations Abstracts International83-01B.
標題:	Microbiology. -
電子資源:	https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28417635
ISBN:	9798516939907

Small Molecule Inhibitors Against Enteric Bacterial Glycosyltransferases.
Zhu, Congrui.

Small Molecule Inhibitors Against Enteric Bacterial Glycosyltransferases. - Ann Arbor : ProQuest Dissertations & Theses, 2021 - 104 p.

Source: Dissertations Abstracts International, Volume: 83-01, Section: B.

Thesis (Ph.D.)--Kansas State University, 2021.

This item must not be sold to any third party vendors.

Enteric bacterial pathogens are the major sources of foodborne diseases. Infection caused by these pathogens leads to gastroenteritis thus of great threat to public health. Pathogenic bacteria evolved to develop various secretion systems to deliver virulence proteins termed 'effectors'. These virulence factors promote the invasion of pathogens as well as evasion of host innate immune response. Type III secretion system (T3SS) is one of the most complex secretion systems used by Gram-negative bacteria Escherichia coli, Salmonella enterica, and Citrobacter rodentium. T3SS resembles a molecular syringe structure to inject secreted effector proteins directly from the bacterial cell into the host cell. Our goal is to look for anti-bacterial virulence therapies by targeting important T3SS effectors.In our first project, we targeted T3SS effector proteins NleB and SseK (NleB ortholog), which are glycosyltransferases that glycosylate protein substrates on arginine residues. This modification is unusual because it occurs on the guanidinium groups of arginines, which are poor nucleophiles, and is distinct from the activity of the mammalian O-linked N-acetylglucosaminyltransferase (OGT). As the deletion of gene nleB significantly attenuates C. rodentium virulence, we aimed to find small molecular inhibitors which specifically bind to NleB. Therefore, we performed high-throughput screening (HTS) assays to identify NleB/SseK inhibitors. We identified two compounds (100066N and 102644N) that significantly inhibited NleB1, SseK1, and SseK2 glycosylation activities. They were also able to inhibit NleB1 glycosylation of the tumor necrosis factor receptor type 1-associated DEATH domain (TRADD) protein in mammalian cells. After pre-incubation with the two compounds in mouse monocyte/macrophage-like cells (RAW264.7), number of Salmonella enterica strain ATCC 14028 which replicated inside RAW264.7 cells greatly reduced 24 h post infection. Results confirmed that 100066N and 102644N can inhibit NleB/SseK activity both in vitro and in vivo. Both compounds can work directly in mammalian cell culture to counter bacterial virulence. Furthermore, 100066N and 102644N show high potential in new drug development because they have advantages of not interfering with bacterial growth curve when added to the LB culture, no significant toxicity to mammalian cells, and do not cross-react with human OGT.However, we encountered difficulties when trying to apply 100066N and 102644N on mice infection models. The two compounds were not easy to synthesize, and their derivatives did not show significant inhibitory effect on bacterial glycosyltransferases. Therefore, in the second project, we screened more NleB/SseK inhibitors by enlarging our libraries to perform HTS assays. These libraries include Analyticon natural products library, ChemDiv 3D Biodiversity, ChemDiv Peptidomimetics, FDA proved drugs, Selleck Bioactives and MayBridge mini library. We identified YM155 (sepantronium bromide) which can inhibit EHEC NleB1, Salmonella SseK1, SseK2, and Citrobacter NleB activities. Like 100066N and 102644N, YM155 also does not interfere with enteric bacterial growth curve when added to the LB culture, has no significant toxicity to mammalian cells nor cross-react with human OGT. Above all, YM155 has the advantage of being more soluble and amenable to chemical derivatization.

ISBN: 9798516939907Subjects--Topical Terms:

536250
Microbiology.
Subjects--Index Terms:

Enteric bacteria

Small Molecule Inhibitors Against Enteric Bacterial Glycosyltransferases.
LDR:04554nmm a2200361 4500 001 2283799
005 20211115071651.5
008 220723s2021 ||||||||||||||||| ||eng d
020 $a 9798516939907
035 $a (MiAaPQ)AAI28417635
035 $a AAI28417635
040 $a MiAaPQ $c MiAaPQ
100 1 $a Zhu, Congrui. $3 3562837
245 1 0 $a Small Molecule Inhibitors Against Enteric Bacterial Glycosyltransferases.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2021
300 $a 104 p.
500 $a Source: Dissertations Abstracts International, Volume: 83-01, Section: B.
500 $a Advisor: Hardwidge, Philip R.
502 $a Thesis (Ph.D.)--Kansas State University, 2021.
506 $a This item must not be sold to any third party vendors.
520 $a Enteric bacterial pathogens are the major sources of foodborne diseases. Infection caused by these pathogens leads to gastroenteritis thus of great threat to public health. Pathogenic bacteria evolved to develop various secretion systems to deliver virulence proteins termed 'effectors'. These virulence factors promote the invasion of pathogens as well as evasion of host innate immune response. Type III secretion system (T3SS) is one of the most complex secretion systems used by Gram-negative bacteria Escherichia coli, Salmonella enterica, and Citrobacter rodentium. T3SS resembles a molecular syringe structure to inject secreted effector proteins directly from the bacterial cell into the host cell. Our goal is to look for anti-bacterial virulence therapies by targeting important T3SS effectors.In our first project, we targeted T3SS effector proteins NleB and SseK (NleB ortholog), which are glycosyltransferases that glycosylate protein substrates on arginine residues. This modification is unusual because it occurs on the guanidinium groups of arginines, which are poor nucleophiles, and is distinct from the activity of the mammalian O-linked N-acetylglucosaminyltransferase (OGT). As the deletion of gene nleB significantly attenuates C. rodentium virulence, we aimed to find small molecular inhibitors which specifically bind to NleB. Therefore, we performed high-throughput screening (HTS) assays to identify NleB/SseK inhibitors. We identified two compounds (100066N and 102644N) that significantly inhibited NleB1, SseK1, and SseK2 glycosylation activities. They were also able to inhibit NleB1 glycosylation of the tumor necrosis factor receptor type 1-associated DEATH domain (TRADD) protein in mammalian cells. After pre-incubation with the two compounds in mouse monocyte/macrophage-like cells (RAW264.7), number of Salmonella enterica strain ATCC 14028 which replicated inside RAW264.7 cells greatly reduced 24 h post infection. Results confirmed that 100066N and 102644N can inhibit NleB/SseK activity both in vitro and in vivo. Both compounds can work directly in mammalian cell culture to counter bacterial virulence. Furthermore, 100066N and 102644N show high potential in new drug development because they have advantages of not interfering with bacterial growth curve when added to the LB culture, no significant toxicity to mammalian cells, and do not cross-react with human OGT.However, we encountered difficulties when trying to apply 100066N and 102644N on mice infection models. The two compounds were not easy to synthesize, and their derivatives did not show significant inhibitory effect on bacterial glycosyltransferases. Therefore, in the second project, we screened more NleB/SseK inhibitors by enlarging our libraries to perform HTS assays. These libraries include Analyticon natural products library, ChemDiv 3D Biodiversity, ChemDiv Peptidomimetics, FDA proved drugs, Selleck Bioactives and MayBridge mini library. We identified YM155 (sepantronium bromide) which can inhibit EHEC NleB1, Salmonella SseK1, SseK2, and Citrobacter NleB activities. Like 100066N and 102644N, YM155 also does not interfere with enteric bacterial growth curve when added to the LB culture, has no significant toxicity to mammalian cells nor cross-react with human OGT. Above all, YM155 has the advantage of being more soluble and amenable to chemical derivatization.
590 $a School code: 0100.
650 4 $a Microbiology. $3 536250
650 4 $a Molecular biology. $3 517296
650 4 $a Endocrinology. $3 610914
653 $a Enteric bacteria
653 $a Glycosyltransferase
653 $a Small molecule inhibitors
653 $a Type three secretion system effectors
690 $a 0410
690 $a 0409
690 $a 0307
710 2 $a Kansas State University. $b Department of Diagnostic Medicine/Pathobiology. $3 1682825
773 0 $t Dissertations Abstracts International $g 83-01B.
790 $a 0100
791 $a Ph.D.
792 $a 2021
793 $a English
856 4 0 $u https://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=28417635